Body composition and risk factors associated with sarcopenia in post-COVID patients after moderate or severe COVID-19 infections

Dulce González-Islas1, Carlos Sánchez-Moreno1, Arturo Orea-Tejeda1*, Samantha Hernández-López1, Fernanda Salgado-Fernández1, Candace Keirns-Davis1, Susana Galicia-Amor2, Esperanza Trejo-Mellado2, Laura Gochicoa-Rangel3 and Armando Castorena-Maldonado4

Abstract

Background: Post-COVID-19 syndrome is characterized by diverse symptoms and abnormalities that persist beyond 12 weeks from the onset of acute COVID-19. Severity disease has been associated with more musculoskeletal alterations such as muscle weakness, dyspnea, and distance walking. The aim was to evaluate the impact of invasive mechanical ventilation (IMV) on body composition and investigate risk factors associated with sarcopenia in post-COVID-19 patients three months after moderate or severe COVID-19 infections.

Methods: Cross-sectional study. 530 patients with PCR-confirmed diagnoses of moderate to severe COVID-19, > 18 years old, oxygen saturation ≤ 93%, PaO2/FiO2 ratio < 300, who required hospitalization and were discharged were included. We excluded those who died before the follow-up visit, declined to participate, or could not be contacted.

Results: The mean age was 53.79 ± 12.90 years. IMV subjects had lower phase angle and handgrip strength and higher impedance index, frequency of low muscle mass, and low muscle strength than those without IMV. The risk factors of sarcopenia were > 60 years of age, diabetes, obesity, IMV, and prolonged hospital stay. The multivariate model showed that age > 60 years (OR: 4.91, 95% CI: 2.26–10.63), obesity (OR: 3.73, 95% CI: 1.21–11.54), and interaction between prolonged length of hospital stay and IMV (OR: 2.92; 95% CI: 1.21–7.02) were related to a higher risk of sarcopenia.

Conclusion: Obesity and the interaction between prolonged length of hospital stay and IMV are associated with a higher risk of sarcopenia at 3 months after severe or moderate COVID-19 infection.

Keywords: Post-COVID-19, Sarcopenia, Body composition, Invasive mechanical ventilation

Introduction

Coronavirus infection disease 2019 (COVID-19) is a viral infection caused by coronavirus-2 (SARS-CoV-2) leading to a severe acute respiratory syndrome in some people that induces a severe inflammatory state, oxidative stress, endothelial damage and microvascular injury, a pro-coagulant state, and maladaptation of the angiotensin-converting enzyme 2 pathway, all of which may contribute to post-COVID syndrome [1–3].
Post-COVID-19 syndrome has been characterized as symptoms and abnormalities persisting beyond 12 weeks from the onset of acute COVID-19 and not attributable to alternative diagnoses [4]. In addition, subjects with moderate or severe COVID-19 infections have more presence or persistence of symptoms such as fatigue or muscle weakness, myalgia, and reduction in quality of health and pulmonary function at six months after the acute infection [5, 6]. At 90 or more days after onset/hospitalization, around 38.4% of this population has been reported to have fatigue or muscle weakness, 33% dyspnea, and 9.7% myalgia [5].

In affected patients, the consequences can be observed at pulmonary, hematologic, cardiovascular, endocrine, renal, gastrointestinal and musculoskeletal levels, as well as and 49.7% developed malnutrition during hospitalization [8].

Regarding musculoskeletal consequences, Pironi et al. observed that subjects admitted to the intensive care unit had more frequency of weight loss > 5% (66.7% vs. 36.5%), as well, the prevalence of nutritional risk (95.7% vs. 67.3) than subjects admitted to intermediate care [7]. Similar results were found in other studies [8, 9]. Several of the factors that may contribute to more significant musculoskeletal alterations include the severity of disease, prolonged hospital stay, pro-inflammatory states and IMV. Huang et al. showed that at six months after acute COVID-19 infection, patients with moderate or severe COVID-19 infections who had undergone IMV compared to those who received oxygen therapy through high-flow nasal cannula had higher frequencies of muscle wasting (81% and 59%, respectively) and less distance walked in a 6 min walk test (29% and 22%, respectively) [6].

On the other hand, low muscular strength or low muscle mass, as well as sarcopenia, are associated with an increased likelihood of adverse outcomes, including falls, fractures, physical disability, diminished capacity for the activities of daily living, and mortality [10–16].

Sarcopenia is a progressive and generalized disorder of skeletal muscle, and the diagnosis is confirmed by low muscular strength and low muscle mass [14].

Different factors contribute to sarcopenia and skeletal muscle disorder such as age, and pre-existing metabolic and inflammatory conditions like diabetes, pulmonary disease, and cardiovascular diseases, pro-inflammatory states, malnutrition, use of corticosteroids, prolonged hospital stay, and IMV [6, 17–24].

Different studies have shown skeletal muscle disorders [7–9] and the possible origins of them in acute COVID-19 [6, 17–24]. However, in post-COVID-19 patients, evidence about body composition alterations and risk factors for sarcopenia is still insufficient. The aim of the present study was to evaluate the impact of IMV on body composition and investigate the risk factors associated with sarcopenia in post-COVID-19 patients at three months after moderate or severe COVID-19 infections.

Material and methods

A cross-sectional study was carried out at Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas”, a level three teaching hospital in Mexico City. Data were obtained from ambulatory patient evaluations three months after acute COVID-19 infection during routine clinical care of post-Covid-19 subjects between June 1, 2020, and June 30, 2021.

Moderate to severe COVID-19 patients with PCR-confirmed diagnosis, > 18 years old, blood oxygen saturation ≤ 93% on room air, PaO2/FiO2 ratio of arterial partial pressure of oxygen to fraction of inspired oxygen < 300 who required hospitalization were discharged and, signed informed consent were included. We excluded those who died before the follow-up visit, declined to participate, or could not be contacted.

Outcome measures

Body composition, anthropometry, pulmonary function, and clinical and demographic variables were performed by a qualified nutritionist and physician and standardized as part of routine studies in the post-COVID-19 clinical management provided to the patients who came to our Institute.

Anthropometry

Weight and height were measured according to the manual reference of anthropometric standardization [25]. All subjects wore light clothing and were barefoot. Body mass index was calculated by dividing the total body weight (kilograms) by the height squared (meters).

Body composition

Body composition was measured with whole-body bioelectrical impedance using four-pole multi-frequency equipment BodyStat QuadScan 4000 (BodyStat, Isle of Man, UK). The standard technique [26] was used: The measurements were all performed by the same operator, in the morning, in a comfortable area, free of drafts, and with portable electric heaters. The subjects were fasting and should not have exercised eight hours before or consumed alcohol 12 h before the study. During the entire study, the subject was in a supine position with arms separated from the trunk at about 30º and legs separated at about 45º.

The area was cleaned with alcohol, and electrodes were placed on the hand and ipsilateral foot. Appendicular skeletal muscle mass (ASMM) was assessed.
according to Sergi’s formula [27]: ASMM (Kg/m²) =  
\[-3.964 + (0.227*(Height² (cm)/Resistance) + (0.095*Weight) + (1.384*Sex) + (0.064*Reactance) /Height (m²)].

**Handgrip strength**

Handgrip strength was measured using a mechanical Smedley Hand Dynamometer (Stoelting, Wood Dale, UK) according to the technique described in Rodriguez et al. [28].

**Sarcopenia**

Sarcopenia was defined according to EWGSOP2 as the presence of low muscle mass (in men ASMM < 20 kg and in women as ASMM < 15 kg) and low muscle strength (in men handgrip strength < 27 kg and in women handgrip strength < 16 kg) [14].

**Respiratory muscle strength**

Maximum inspiratory pressures (MIP) and maximum expiratory pressures (MEP) were measured based on ATS/ERS 2002 recommendations using MicroRPM equipment (CareFusion, Micromedical, UK) [29].

**Statistical analysis**

Analyses were performed using the commercially available package STATA version 14 (Stata Corp., College Station, TX, U.S.A.). Categorical variables were expressed as frequencies and percentages. The Shapiro–Wilk test was used to assess the normality of continuous variables; normal continuous variables were expressed as mean and standard deviation, while non-normal variables were expressed as median and percentiles 25–75. A comparison among study groups (subjects with IMV and without IMV) was analyzed with X² for categorical variables and unpaired Student’s t-test or Mann Whitney U tests for continuous variables. A simple logistic regression model to evaluate the risk factors associated with sarcopenia was performed to estimate the odds ratio (OR) and 95% Confidence Intervals (CI). Risk factors with p-value < 0.20 in the unadjusted model were included in the full multivariable regression model, and then stepwise selection (p-value ≤ 0.20 as “in” criteria and p-value ≥ 0.05 as “out” criteria) was applied to generate the final model. These associations were adjusted for sex and, diabetes, VIH, COPD and, PaO₂/FiO₂ ratio. A p < 0.05 was considered to be statistically significant.

**Results**

A total of 530 post-COVID subjects were included. The age median age was 53.79 ± 12.90 years, and 60.94% were males.

Subjects managed with IMV had a higher prevalence of ischemic cardiopathy, a longer hospital stay (25 [17–36] vs. 9 [7–13], p < 0.001), lower arterial oxygen saturation (81.5 [69.1–90] vs. 86.7 [81–91], p < 0.001), PaO₂ (49.7 [36.1–65.3] vs. 55 [45.8–67.5], p < 0.010), and PaO₂/FiO₂ ratio (129.52 [90.93–176.09] vs. 226.42 [172.99–264.76], p < 0.001), besides more frequency of acute respiratory distress syndrome moderate-severe (86% vs. 41.33%, p < 0.001) at admission than subjects who were not treated with IMV. Duration of IMV were 17 [10–29] days.

Regarding body composition, subjects exposed to IMV had lower phase angle, handgrip strength, and higher impedance index, frequency of low muscle mass, and low muscle strength (Table 1).

The risk factors associated with sarcopenia were >60 years of age, diabetes, obesity, IMV, duration of IMV, and hospital stay > 7 days (Table 2). The multivariate model showed that age > 60 years, obesity and the interaction between prolonged hospital stay and IMV were associated with a higher risk of sarcopenia (Table 3).

**Discussion**

There were two main findings from this study. The first involved the differences in body composition alterations, especially skeletal muscle abnormalities, in post-COVID-19 survivors who had undergone IMV and those who had not. The second was the identification of risk factors associated with sarcopenia.

In our population, 47.36% had low muscle strength. This was an independent predictor of poor patient outcomes such as persistent fatigue, diminished capacity to perform activities of daily living, pulmonary function, physical functioning, prolonged hospital stay, poor health-related quality of life, and mortality in other populations [11, 12, 15, 16, 30–32]. Cheval et al. also showed that muscle strength was an independent risk factor for COVID-19 hospitalization (OR: 0.64, 95% CI: 0.45–0.92, p = 0.015) [33].

In addition, at six months after acute COVID-19, the most frequent consequences were fatigue or muscle weakness [6]. In our population, 24.5% had low muscle mass; this was another important independent predictor of worsening capacity to perform activities of daily living, falls, and mortality [16, 34].

Sarcopenia is defined as the presence of both low muscle mass and low muscle function and increases the risk of adverse outcomes such as physical disability and mortality [14, 35, 36]. In our population, 18.49% had sarcopenia. One of the factors that may contribute to the development of sarcopenia in post-COVID-19 patients is age. It has been reported that individuals more than fifty years old undergo a 1–2% loss of muscle mass and a loss of muscular strength of about 1.5–5% per year [37].
In adults > 60 years of age, the prevalence of sarcopenia was 10% [38]. In our study, the risk of sarcopenia in subjects > 60 years old increased five times (OR: 4.91, 95% CI: 2.26–10.63, *p* < 0.001) adjusted to confounding variables.

Another important risk factor for sarcopenia is prolonged hospitalization. Patients with moderate to severe COVID-19 had prolonged hospital stays. Those requiring supplemental oxygen remained a median of 14 days (10–18), while those with high-flow nasal cannula for oxygen therapy or IMV were in the hospital for a median of 35 days (22–51) [6]. In our study, the mean length of hospital stay was 25 days (17–36) for IMV subjects and nine

---

**Table 1** Clinical characteristics and body composition of Post-COVID-19 patients subdivided by invasive mechanical ventilation utilization

|                             | All n = 530 | Invasive mechanical ventilation n = 329 | No Invasive mechanical ventilation n = 116 | *p*-value |
|-----------------------------|-------------|----------------------------------------|--------------------------------------------|-----------|
| **Age, years**              | 53.79 ± 12.90 | 53.43 ± 12.43 | 54.39 ± 13.65 | 0.403     |
| Male, n (%)                 | 323 (60.94)  | 207 (62.92) | 116 (57.47) | 0.233     |
| Diabetes, n (%)             | 149 (28.11)  | 83 (25.23) | 66 (32.84) | 0.059     |
| Hypertension, n (%)         | 166 (31.32)  | 103 (31.31) | 63 (31.34) | 0.993     |
| Obesity, n (%)              | 298 (75.25)  | 192 (73.85) | 106 (77.94) | 0.370     |
| Ischemic cardiopathy, n (%) | 37 (6.98)   | 21 (10.45) | 16 (8.60) | 0.014     |
| Pulmonary disease, n (%)    | 84 (15.85)  | 52 (15.81) | 32 (15.92) | 0.972     |
| Thyroid disease, n (%)      | 22 (4.15)   | 10 (3.04) | 12 (5.97) | 0.101     |
| Hepatopathy, n (%)          | 19 (3.58)   | 14 (4.26) | 5 (2.49) | 0.288     |
| HIV, n (%)                  | 3 (0.57)    | 2 (0.61) | 1 (0.5) | 0.869     |
| Asthma (%)                  | 12 (2.26)   | 7 (2.13) | 5 (2.49) | 0.787     |
| COPD, n (%)                 | 9 (1.7)     | 4 (1.22) | 5 (2.49) | 0.272     |

**Hospitalary parameters**

| Length of hospital stay, d  | 17 [10–29] | 25 [17–36] | 9 [7–13] | <0.001 |
| Duration of IMV            | 13 [9–20] | 13 [9–20] | – | – |
| Arterial oxygen saturation, % | 85 [73–90.6] | 81.5 [69.1–90] | 86.7 [81–91] | <0.001 |
| PaO2%                       | 52.75 [40.35–66.1] | 49.7 [36.1–65.3] | 55 [45.8–67.5] | 0.010 |
| PaO2/FiO2 ratio            | 156.35 [105.04–212.85] | 129.52 [90.93–176.09] | 226.42 [172.99–264.76] | <0.001 |
| ARDS mild, n (%)           | 72 (26.18) | 28 (14) | 44 (21.33) | <0.001 |
| ARDS moderate-severe, n (%) | 203 (73.82) | 172 (76) | 16 (76) | 0.019 |

**Body composition at 3 months**

| Weight, kg                  | 77 [68–86.8] | 76.1 [67–85] | 79 [69–87.3] | 0.112 |
| Height, cm²                 | 161.69 ±8.88 | 161.37 ±8.67 | 162.23 ± 9.2 | 0.279 |
| Body mass index, kg/m²      | 20.05 [25.9–32.86] | 20.05 [25.63–32.65] | 20.03 [26.34–33.2] | 0.431 |
| Fat Mass, %                 | 24.13 [18.42–31.31] | 24.13 [17.87–31.62] | 24.13 [19.68–31.03] | 0.553 |
| FFMI, kg                    | 19.92 ±3.21 | 19.93 ±3.10 | 19.89 ±3.43 | 0.917 |
| ASMMI, kg                   | 20.33 [17.31–23.19] | 20.12 [17.37–22.89] | 20.86 [17.24–23.77] | 0.091 |
| ASMMI, kg                   | 7.71 [7.01–8.51] | 7.68 [6.99–8.42] | 7.84 [7.10–8.64] | 0.129 |
| Phase angle, °              | 6.1 [5.3–6.9] | 5.9 [5.6–7] | 6.55 [5.7–7.2] | <0.001 |
| Impedance index, 200/50 kHz | 0.8 [0.77–0.83] | 0.81 [0.78–0.83] | 0.78 [0.76–0.81] | <0.001 |
| Handgrip strength, kg       | 23.6 ±9.32 | 22.07 ±9.11 | 26.09 ±9.15 | <0.001 |
| MIP, cmH₂O                   | 94.04 ±26.89 | 92.64 ±25.7 | 96.38 ±28.61 | 0.137 |
| MIP < 80% pred, n (%)       | 117 (22.08) | 74 (22.49) | 43 (21.39) | 0.767 |
| MIP < 80% pred, n (%)       | 115.19 ±35.46 | 114.25 ±33.96 | 116.7 ±37.82 | 0.460 |
| Low muscle mass, n (%)      | 404 (76.23) | 255 (77.51) | 149 (74.13) | 0.375 |
| Low muscle mass, n (%)      | 130 (24.53) | 92 (27.96) | 38 (18.91) | 0.019 |
| Low muscle strength, n (%)  | 251 (47.36) | 192 (58.36) | 59 (29.35) | <0.001 |
| Sarcopenia, n (%)            | 98 (18.49) | 74 (22.49) | 24 (11.94) | 0.069 |

HIV, Human immunodeficiency virus; COPD, Chronic Obstructive Pulmonary Disease; VMI, Ventilation mechanical invasive; PaO2, Arterial partial pressure of oxygen; PaO2/FiO2, Arterial partial pressure of oxygen/ Fraction of inspired oxygen; ARDS,Acute Respiratory Distress Syndrome; FFMI, Fat Free Mass Index; ASMM, Appendicular skeletal muscle mass, ASMMI, Appendicular skeletal muscle mass index, MIP, Maximum inspiratory pressures; MEP, Maximum expiratory pressures.
Table 2 Risk factors associated to sarcopenia in Post-COVID patients. Bivariate model

| Risk Factor                          | OR     | CI 95%    | p-value |
|--------------------------------------|--------|-----------|---------|
| >60 years old                        | 3.98   | 2.46–6.45 | <0.001  |
| Male                                 | 0.96   | 0.61–1.50 | 0.868   |
| Diabetes                             | 1.63   | 1.03–2.60 | 0.037   |
| Hypertension                         | 1.27   | 0.80–2.02 | 0.300   |
| Obesity                              | 2.17   | 1.06–4.43 | 0.033   |
| Ischemic cardiopathy                 | 1.03   | 0.43–2.42 | 0.945   |
| Pulmonary disease                    | 1.14   | 0.63–2.05 | 0.653   |
| Thyroid disease                      | 0.68   | 0.19–2.36 | 0.551   |
| Hepatopathy                          | 1.18   | 0.38–3.64 | 0.770   |
| VIH                                  | 8.97   | 0.80–100.03 | 0.074 |
| Asthma                               | 0.39   | 0.05–3.09 | 0.376   |
| COPD                                 | 3.63   | 0.95–13.79 | 0.058 |
| Hospitalary parameters               |        |           |         |
| IMV                                  | 2.14   | 1.29–3.52 | 0.003   |
| Duration of IMV, d                   | 1.05   | 1.01–1.09 | 0.003   |
| Prolonged length of hospital stay, > 7 d | 3.04 | 1.64–5.63 | <0.001  |
| Arterial oxygen saturation, %        | 1.00   | 0.98–1.02 | 0.797   |
| PaO2, %                              | 0.99   | 0.97–1.00 | 0.415   |
| PaO2/FiO2 ratio                      | 0.99   | 0.99–1.00 | 0.054   |
| ARDS mild                            | 1      | Reference |         |
| ARDS moderate-severe                 | 1.71   | 0.78–3.74 | 0.174   |

HIV, Human Immunodeficiency Virus; COPD, Chronic Obstructive Pulmonary Disease; IMV, Invasive Mechanical Ventilation; PaO2, Arterial partial pressure of oxygen; PaO2/FiO2, Arterial partial pressure of oxygen/Fraction of inspired oxygen; ARDS, Acute Respiratory Distress Syndrome

Table 3 Risk factors associated to sarcopenia in Post-COVID patients. Multivariate model

| Risk Factor                          | OR     | CI 95%    | p-value |
|--------------------------------------|--------|-----------|---------|
| Age > 60 years                       | 4.91   | 2.26–10.63 | <0.001  |
| Obesity                              | 3.73   | 1.21–11.54 | 0.022   |
| IMV* Prolonged length of hospital stay, > 7 d | 2.92 | 1.21–7.02 | 0.016   |

IMV, Invasive mechanical invasive; *Adjusted for age and diabetes, VIH, COPD, and PaO2/FiO2 ratio

It is estimated that between 60 and 80% of IMV patients had diaphragmatic weakness [19, 40], which is associated with prolonged IMV and mortality [39, 46]. Global respiratory muscle strength is evaluated by maximum inspiratory pressure (MIP), which estimates the strength of the inspiratory muscles (diaphragm), and maximal expiratory pressure MEP, which estimates the strength of the intercostal and abdominal muscles. In COVID-19 patients 30 days after being discharged from the hospital, Huang et al. demonstrated low respiratory muscle strength in both inspiratory and expiratory muscles (52.9% had MIP < 80% of predicted and 23.5% had MEP < 80% of predicted, respectively) [47]. In our population, three months after acute COVID-19 infection we found that 22.08% had low strength of the inspiratory muscles, and 76.23% had low strength of the expiratory muscles. There was no difference in declining respiratory muscle strength between those managed with IMV and those who were not. This finding concurred with Huang et al. report [47]: pulmonary function is reduced in COVID-19 survivors. Salem et al. showed decreases in total lung capacity, forced vital capacity (FVC), forced expiratory volume (FEV1), FEV1/FEV, and diffusing capacity for carbon monoxide [48]. Prior evidence in
Another of the risk factors associated with sarcopenia involves the pro-inflammatory elements [51, 52]. In acute COVID-19, elevated levels of pro-inflammatory markers have been documented, and they are higher in patients with severe COVID-19 and non-survivors than in stable subjects [2, 3]. Elevation of these pro-inflammatory cytokines like IL-1β, IL-6, TNF-α, interferon-γ, as well CRP and NF-xB, induce muscle fiber proteolysis and decrease protein synthesis [17, 20, 53, 54]. In addition, pro-inflammatory factors are associated with lower skeletal muscle strength and low muscle mass and increased risk of sarcopenia [51, 52]. Pre-existing comorbidities also increase the risk of sarcopenia; in our study, after adjusting for confounding variables, obesity was associated with greater risk of sarcopenia, similar to results found previously [21, 55]. Obesity has also been associated with increased inflammatory markers, production of reactive oxygen species, insulin resistance, and fat infiltration, promoting muscle catabolism and inhibiting muscle anabolic pathways [56].

In the case of diabetes, this was associated to sarcopenia in bivariate model but not in multivariate, however the evidence in other studies showed that insulin resistance increases protein degradation and reduces protein synthesis. This initiates a vicious cycle since loss of muscle mass has a negative impact on insulin resistance, and muscle is a target tissue of insulin [57].

Moreover, malnutrition plays an essential role in the loss of muscle mass during hospitalization. At the same time, the most common digestive symptoms in patients with COVID-19 are nausea, vomiting, diarrhea, and loss of appetite [58]. These symptoms may impact nutritional status and body composition with loss of muscle mass. In COVID-19 hospitalized patients, malnutrition was 42.1%, which increased to 66.7% in patients admitted to the intensive care unit [59]. A meta-analysis performance by Ojo et al. in critically ill patients with COVID-19 showed that early enteral nutrition reduced 11% the risk of mortality (RR: 89, 95%CI; 0.79 to 0.99) and a reduction in SOFA score [60].

Strength and limitations of the study
This study has the inherent limitations of a cross-sectional study: It is impossible to assess causality, and we cannot know the incidence of sarcopenia during hospitalization for COVID-19. Another limitation is that we did not evaluate inflammation markers to determine their association with sarcopenia in post-COVID-19 subjects. However, among its strengths, this is the first study in post-COVID-19 patients that assesses body composition comparing patients managed with and without IMV in association with risk factors for sarcopenia using a multivariate prediction model adjusted for confounding variables. This provides us with a profile of the musculoskeletal alterations of these subjects after their hospitalization.

Conclusion
In post-COVID-19 patients, the interaction between prolonged length of hospital stay > 7 days and IMV and obesity lead to a greater risk of sarcopenia at three months after severe or moderate COVID-19 infection.

Abbreviations
ASMM: Appendicular skeletal muscle mass; CI: Confidence intervals; COVID-19: Coronavirus infection disease 2019; IMV: Invasive mechanical ventilation; MIP: Maximum inspiratory pressure; MEP: Maximum expiratory pressure; OR: Odds ratio; PaO2/FIO2: Arterial partial pressure of oxygen/Fraction of inspired oxygen; SARS-CoV-2: Severe acute respiratory syndrome-coronavirus-2.

Acknowledgements
To the Cardiology Service team. All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

Author contributions
Conceptualization; G-ID and O-TA. Data curation; S-MC and H-LS. Formal analysis; G-ID. Investigation; S-MC, O-TA, H-LS, S-FF, K-DC, T-ME and C-MA. Resources; S-MC and T-ME. Methodology; H-LS, S-FF, K-DC and G-RL. Project administration; G-ID, O-TA, G-AS, G-RL and C-MA. Supervision; G-AS. Roles/Writing—original draft; G-ID, S-MC, O-TA, H-LS, S-FF, G-AS, T-ME, G-RL and C-MA. Writing—review and editing; G-ID, S-MC, O-TA, H-LS, S-FF, G-AS, T-ME, G-RL and C-MA. All authors read and approved the final manuscript.

Funding
The authors declare that there is no funding in the present study.

Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available due to the fact that individual privacy could be compromised but are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Ethics and Research Committee of Biomedical Research in Humans of the Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas” (approval number C57-21), and all participants signed informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Heart Failure and Respiratory Distress Clinic, Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas”, Calzada de Tlalpan 4502 Col Sec XVI CP 14080 Del Tlalpan, Mexico City, Mexico. 2Pulmonary Rehabilitation Department, Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas”, Mexico City, Mexico. 3Department of Pulmonary Physiology, Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas”, Mexico City, Mexico.
Acknowledgments

We would like to thank the members of the research team for their contributions to this study.

Competing Interests

The authors declare that they have no competing interests.

Funding Sources

This work was supported by the National Natural Science Foundation of China (82071796) and Jiangsu Natural Science Foundation for Young Scholars (BK20190098). The funder had no role in the study design, data collection, analysis, interpretation, or writing of the report.

References

1. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Mahajan S, et al. Extra pulmonary manifestations of COVID-19: A review. J Med Microbiol. 2020;69(1):1029–32.
2. McElvaney OJ, McEvoy NL, McElvaney OF, Carroll TP, Murphy MP, Dunlea DM, et al. Characterisation of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med. 2020;202(6):812–21.
3. Udomniprasert W, Jittikoon J, Sangroongruangsi S, Chaikledekaew U. Circulating levels of interleukin-6 and interleukin-10, but not tumor necrosis factor-alpha, as potential biomarkers of severity and mortality for COVID-19: a systematic review with meta-analysis. J Clin Immunol. 2021;41(1):11–22.
4. COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: © Nice, 2020 Dec 18.
5. Fernández-de-Las-Peñas C, Palacios-Ceja D, Gómez-Mayordomo V, Florencio LC, Cuadrado ML, Plaza-Manzano G, et al. Prevalence of post-COVID-19 survivors: a systematic review and meta-analysis. Eur J Intern Med. 2021;92:55–70.
6. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220–32.
7. Pironi L, Sasdelli AS, Ravaoli F, Baracco B, Battiala C, Bocchioli G, et al. Malnutrition and nutritional therapy in patients with SARS-CoV-2 disease. Clin Nutr. 2021;40(3):1330–7.
8. Allard L, Ouedraogo E, Molleville J, Bihan H, Giroux-Leprieur B, Sutton A, et al. Malnutrition: percentage and association with prognosis in patients hospitalized for coronavirus disease 2019. Nutrients. 2020;12(12):3679.
9. Dr. Filippo L, De Lorenzo R, D’Amico M, Sofia V, Roveri L, Mele R, et al. COVID-19 is associated with clinically significant weight loss and risk of malnutrition, independent of hospitalisation: a post-hoc analysis of a prospective cohort study. Clin Nutr. 2021;40(4):2420–6.
10. Beaudart C, Zaaria M, Pasleau F, Reginster JY, Bruyère O. Health outcomes of sarcopenia: a systematic review and meta-analysis. PLOSE ONE. 2017;12(1):0169548.
11. Celis-Morales CA, Welsh P, Lyall DM, Steele I, Petersmann F, Anderson J, et al. Associations of grip strength with cardiovascular, respiratory, and cancer outcomes and all cause mortality: prospective cohort study of half a million UK Biobank participants. BMJ. 2018;361:k1651.
12. García-Hermoso A, Cavero-Redondo I, Ramírez-Vélez R, Ruiz JR, Ortega FB, Lee DC, et al. Muscular strength as a predictor of all-cause mortality in an apparently healthy population: a systematic review and meta-analysis of data from approximately 2 million men and women. Arch Phys Med Rehabil. 2018;99(10):2100–13.
13. Yang T, Li Z, Jiang L, Xi X. Corticosteroid use and intensive care unit-acquired weakness: a systematic review and meta-analysis. Crit Care (Lond Engl). 2018;22(11):187.
14. Cruz-Jentoft AJ, Alquy G, Bauer J, Bosire Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31.
15. Jochem C, Leitzmann M, Volaklis K, Aune D, Strasser B. Association between muscular strength and mortality in clinical populations: a systematic review and meta-analysis. J Am Med Dir Assoc. 2019;20(10):1213–23.
16. Wang DM, Yao J, Zirek Y, Reijniere EM, Maier AB. Muscle mass, strength, and physical performance predicting activities of daily living: a meta-analysis. J Cachexia Sarcopenia Muscle. 2020;11(1):3–25.
17. Reid MB, Li YP. Tumor necrosis factor-alpha and muscle wasting: a cellular perspective. Respir Res. 2001;2(3):269–72.
18. Alley DE, Koster A, Mackey D, Cawthon P, Ferrucci L, Simonsick EM, et al. Hospitalization and change in body composition and strength in a population-based cohort of older persons. J Am Geriatr Soc. 2010;58(11):2085–91.
19. Dres M, Dubé BP, Mayaux J, Delemazure J, Reuter D, Brochard L, et al. Coexistence and impact of limb muscle and diaphragm weakness at time of liberation from mechanical ventilation in medical intensive care unit patients. Am J Respir Crit Care Med. 2017;195(1):57–66.
20. Forcina L, Miano C, Scocchitano BM, Rizzuto E, Berardinelli MG, De Benedetti F, et al. Increased circulating levels of interleukin-6 affect the redox balance in skeletal muscle. Oxidative Med Cell Longev. 2019;2019:3018584.
21. Yang L, Smith L, Hamer M. Gender-specific risk factors for incident sarcopenia: 8-year follow-up of the English longitudinal study of ageing. J Epidemiol Commun Health. 2019;73(1):86–8.
22. Disser NP, De Michelli AJ, Schonk MM, Konnaris MA, Piccianti AN, Edon DL, et al. Musculoskeletal consequences of COVID-19. J Bone Joint Surg. 2020;102(14):1197–204.
23. Pacifico J, Geerlings MAL, Reijniere EM, Phassouliotis C, Lim WK, Maier AB. Prevalence of sarcopenia as a comorbid disease: a systematic review and meta-analysis. Exp Gerontol. 2020;131:110801.
24. Sato PHR, Ferreira AA, Rosado EL. The prevalence and risk factors for sarcopenia in older adults and long-living older adults. Arch Gerontol Geriat. 2020;89:104089.
25. Lohman TG, Roche AF, Martorell R. Anthropometric standardization reference manual. Champaign: Human Kinetics Books; 1988.
26. Lukasch HJ, Johnson PE, Bolzetta F, Berton L, Carraro S, et al. Assessing appendicular skeletal muscle mass with biochemical impedance measurements of the human body. Am J Clin Nutr. 1985;41(4):810–7.
27. Sergi G, De Rui M, Veronese N, Bolzetta F, Berton L, Carraro S, et al. Assessing appendicular skeletal muscle mass with biochemical impedance analysis in free-living Caucasian older adults. Clin Nutr. 2015;34(4):667–73.
28. Rodríguez-García WD, García-Castañeda L, Orea-Tejeda A, Mendoza-Núñez V, González-Islas DG, Santillán-Díaz C, et al. Handgrip strength: Reference values and its relationship with bioimpedance and anthropometric variables. Clin Nutr ESPEN. 2017;19:54–8.
29. ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med. 2002;166(4):518–624.
30. Balsamo S, da Mota LM, de Carvalho JM, Nascimento DDC, Tibana RA, de Santana FS, et al. Low dynamic muscle strength and its associations with fatigue, functional performance, and quality of life in premenopausal patients with systemic lupus erythematosus and low disease activity: a case-control study. BMC Musculoskelet Disord. 2013;8(14):263.
31. Chen L, Liu X, Wang Q, Jia L, Song K, Nie S, et al. Better pulmonary function is associated with greater handgrip strength in a healthy Chinese Han population. BMC Pulm Med. 2020;20(1):114.
32. Chites VS, Teixeira PP, Lima J, Burgel CF, Gattermann Pereira T, Silva FM. Reduced handgrip strength in hospital admission predicts prolonged hospital stay and death but is not accurate to identify malnutrition: a longitudinal study of reduced handgrip strength in hospitalized patients. JPEN J Parenter Enter Nutr. 2021;45(5):1016–22.
33. Cheval B, Sieber S, Maltagliati S, Millet GP, Formánek T, Chalabaev A, et al. Muscle strength is associated with COVID-19 hospitalization in adults 50 years of age or older. J Cachexia Sarcopenia Muscle. 2021;65:1529.
34. Kim EY, Jun KH, Kim SY, Chun HM. Body mass index and skeletal muscle mass index are useful prognostic factors for overall survival after gastrectomy for gastric cancer: Retrospective cohort study. Medicine. 2020;99(47):e23363.
35. Chang CF, Yeh YL, Chang HY, Tsai SH, Wang JY. Prevalence and risk factors of sarcopenia among older adults aged ≥ 65 years admitted to daycare centers of Taiwan: using AWGS 2019 guidelines. Int J Environ Res Public Health. 2021;18(16):8299.
36. Xu J, Wan CS, Ktioris K, Reijniere EM, Maier AB. Sarcopenia is associated with mortality in adults: a systematic review and meta-analysis. Gerontology. 2021;1–16.
37. Keller K, Engelhardt M. Strength and muscle mass loss with aging process: age and strength loss. Muscles Ligaments Tendons J. 2013;3(4):346–50.
38. Shafiee G, Keshkhar A, Soltani A, Ahadi Z, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta-analysis of general population studies. J Diabetes Metab Disord. 2017;16:21.
39. Demoule A, Jung B, Prodanovic H, Molinari N, Chambes G, Coirault C, et al. Handgrip dysfunction on admission to the intensive care unit:
